Skip to main content
. Author manuscript; available in PMC: 2012 Feb 29.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Oct;55(2):189–196. doi: 10.1097/QAI.0b013e3181e46308

Figure 2.

Figure 2

Influenza-specific salivary IgG antibody responses to LAIV and TIV in HIV-infected children on HAART. Data were derived from 234 HIV-infected children randomly assigned to receive LAIV or TIV during the 2004–2005 influenza season. Bars represent geometric mean titers (GMT) and 95% CI. For the subjects who did not have detectable influenza-IgG in the saliva (N of 19, 7 and 6 at weeks 0, 4 and 24, respectively), an arbitrary value of 0.001 was used for the analysis. Baseline values were similar in both treatment groups. The increase from baseline in the influenza-IgG concentrations was significantly higher in TIV compared with LAIV recipients at week 4 (p=0.05; F test), but not at week 24 (p=0.12; F test).